These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34127806)

  • 1. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
    Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
    Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor suppresses prostate cancer metastasis but promotes bladder cancer metastasis via differentially altering miRNA525-5p/SLPI-mediated vasculogenic mimicry formation.
    Yang Z; Chen J; Xie H; Liu T; Chen Y; Ma Z; Pei X; Yang W; Li L
    Cancer Lett; 2020 Mar; 473():118-129. PubMed ID: 31843555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression.
    Wu G; Sun Y; Xiang Z; Wang K; Liu B; Xiao G; Niu Y; Wu D; Chang C
    Cell Death Dis; 2019 Jan; 10(2):37. PubMed ID: 30674872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
    Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
    Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer.
    Liu B; Sun Y; Tang M; Liang C; Huang CP; Niu Y; Wang Z; Chang C
    Cell Death Dis; 2020 Sep; 11(9):807. PubMed ID: 32978369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.
    Hu S; Li L; Yeh S; Cui Y; Li X; Chang HC; Jin J; Chang C
    Mol Oncol; 2015 Jan; 9(1):44-57. PubMed ID: 25135278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression.
    Zhang M; Sun Y; Huang CP; Luo J; Zhang L; Meng J; Liang C; Chang C
    Cell Death Dis; 2021 Sep; 12(10):855. PubMed ID: 34545067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion.
    Chen J; Sun Y; Ou Z; Yeh S; Huang CP; You B; Tsai YC; Sheu TJ; Zu X; Chang C
    EMBO Rep; 2020 Apr; 21(4):e48467. PubMed ID: 32052578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
    Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
    Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
    Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C
    Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The miRNAs 203a/210-3p/5001-5p regulate the androgen/androgen receptor/YAP-induced migration in prostate cancer cells.
    Huo C; Kuo YY; Lin CY; Shiah SG; Li CY; Huang SP; Chen JK; Wang WC; Kung HJ; Chuu CP
    Cancer Med; 2024 Aug; 13(16):e70106. PubMed ID: 39149855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals.
    Wang K; Sun Y; Tao W; Fei X; Chang C
    Cancer Lett; 2017 May; 394():1-12. PubMed ID: 28089832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals.
    Ou Z; Wang Y; Liu L; Li L; Yeh S; Qi L; Chang C
    Oncotarget; 2015 Sep; 6(28):26065-78. PubMed ID: 26305549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASC-J9
    Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
    Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knocking down AR promotes osteoblasts to recruit prostate cancer cells by altering exosomal circ-DHPS/miR-214-3p/CCL5 pathway.
    Yang Z; Chen JQ; Liu TJ; Chen YL; Ma ZK; Fan YZ; Wang ZX; Xu S; Wang K; Wang XY; Li L; Xie HJ
    Asian J Androl; 2024 Mar; 26(2):195-204. PubMed ID: 37966336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.